DPP-4 inhibitors may have specific autoimmune risks
MDSpire News
September 24, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

DPP-4 inhibitors may increase the risk of certain autoimmune diseases compared to GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes patients.
The study analyzed data from 152 healthcare organizations, including 118,419 matched pairs of DPP-4 inhibitors and GLP-1 receptor agonists.
DPP-4 inhibitors were associated with a higher likelihood of dermatomyositis and bullous pemphigoid, while showing a lower likelihood of psoriasis and autoimmune thyroiditis.
No significant differences in autoimmune disease risk were found between GLP-1 receptor agonists and SGLT2 inhibitors after adjusting for multiple comparisons.
The study's observational design had limitations, including potential selection bias and incomplete capture of risk factors, affecting the reliability of the findings.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: